Clinical trial
A Randomized, Double-blind, Placebo-controlled Phase 3 Study to Evaluate the Efficacy, Safety, Pharmacokinetics, and Pharmacodynamics of ANX005 in Subjects With Guillain-Barré Syndrome
NCT04701164 is registered in ClinicalTrials.gov with Annexon, Inc. as lead sponsor.
Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.
Registry record
As filed in ClinicalTrials.gov.
- Title
- A Randomized, Double-blind, Placebo-controlled Phase 3 Study to Evaluate the Efficacy, Safety, Pharmacokinetics, and Pharmacodynamics of ANX005 in Subjects With Guillain-Barré Syndrome
- Lead sponsor
- Annexon, Inc.
- Phase
- Phase 3
- Overall status
- Completed
- Start date
- December 17, 2020
- Completion date
- April 20, 2024
- Enrollment
- 242 (actual)
- Sites
- 11
Conditions
As the registry lists them; a condition with its own page is linked.